ATE227120T1 - Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen - Google Patents

Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen

Info

Publication number
ATE227120T1
ATE227120T1 AT98921701T AT98921701T ATE227120T1 AT E227120 T1 ATE227120 T1 AT E227120T1 AT 98921701 T AT98921701 T AT 98921701T AT 98921701 T AT98921701 T AT 98921701T AT E227120 T1 ATE227120 T1 AT E227120T1
Authority
AT
Austria
Prior art keywords
testosterone
devices
precursor compounds
intravaginal administration
precursor
Prior art date
Application number
AT98921701T
Other languages
English (en)
Inventor
Clare Passmore
Claire Gilligan
Original Assignee
Galen Chemicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galen Chemicals Ltd filed Critical Galen Chemicals Ltd
Application granted granted Critical
Publication of ATE227120T1 publication Critical patent/ATE227120T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98921701T 1997-05-07 1998-05-07 Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen ATE227120T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE970333 1997-05-07
PCT/IE1998/000033 WO1998050016A2 (en) 1997-05-07 1998-05-07 Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors

Publications (1)

Publication Number Publication Date
ATE227120T1 true ATE227120T1 (de) 2002-11-15

Family

ID=11041465

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98921701T ATE227120T1 (de) 1997-05-07 1998-05-07 Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen

Country Status (15)

Country Link
US (1) US6416780B1 (de)
EP (1) EP0981327B1 (de)
JP (1) JP2001524124A (de)
CN (1) CN1184957C (de)
AT (1) ATE227120T1 (de)
AU (1) AU741482B2 (de)
CA (1) CA2288046C (de)
DE (1) DE69809222T2 (de)
DK (1) DK0981327T3 (de)
ES (1) ES2187024T3 (de)
IL (1) IL132702A0 (de)
NO (1) NO995419L (de)
NZ (1) NZ501236A (de)
PT (1) PT981327E (de)
WO (1) WO1998050016A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ES2388731T5 (es) * 2002-03-27 2018-01-19 Warner Chilcott (Ireland) Limited Dispositivos de administración de fármacos mediante una matriz intravaginal
US8399013B2 (en) * 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
US8404272B2 (en) * 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
EP3470108A1 (de) 2004-07-02 2019-04-17 Mati Therapeutics Inc. Vorrichtung zur abgabe eines behandlungsmittels im auge
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
ES2400091T3 (es) * 2005-08-11 2013-04-05 Massachusetts Institute Of Technology Dispositivo de suministro de fármacos intravesical y método
DK2010096T3 (en) 2006-03-31 2017-10-02 Mati Therapeutics Inc NASOLACRIMAL DRAINAGE SYSTEM IMPLANTS FOR PHARMACEUTICAL THERAPY
BRPI0719210A2 (pt) 2006-10-12 2015-05-05 Xenon Pharmaceuticals Inc Uso de compostos espiro-oxindol como agentes terapêuticos
CN101896221B (zh) 2007-12-11 2013-06-05 麻省理工学院 用于治疗膀胱和其它体囊或体腔的可植入式药物递送设备和方法
SI2249757T1 (sl) * 2008-02-04 2017-10-30 Ferring B.V. Monolitni intravaginalni obroč, ki vsebuje progesteron ter postopki za njegovo izdelavo in uporabo
US9034365B2 (en) 2008-05-20 2015-05-19 Poly-Med, Inc. Biostable, multipurpose, microbicidal intravaginal devices
KR101689786B1 (ko) 2008-08-09 2016-12-26 메사츄세츠 인스티튜트 어브 테크놀로지 남성 비뇨생식기 및 주위 조직을 치료하는 방법 및 체내이식형 약물 전달 장치
CA2741029A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010078307A1 (en) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
CN102470237A (zh) 2009-06-26 2012-05-23 塔里斯生物医药公司 用于可植入药物递送装置的固体药物片剂
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US9017312B2 (en) * 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
EP2488531B1 (de) 2009-10-14 2014-03-26 Xenon Pharmaceuticals Inc. Verfahren zur herstellung von spiro-oxindol derivaten
EP3266444A1 (de) 2010-02-26 2018-01-10 Xenon Pharmaceuticals Inc. Pharmazeutische zusammensetzungen einer spirooxindolverbindung zur topischen verabreichung und deren verwendung als therapeutika
WO2012096985A1 (en) 2011-01-10 2012-07-19 Taris Biomedical, Inc. Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
BR112013019410A2 (pt) 2011-02-04 2019-09-24 Taris Biomedical Inc dispositivo implantável para liberação controlada de fármaco de solubilidade baixa
WO2013030679A2 (en) 2011-08-29 2013-03-07 Qlt Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2014144658A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Dual reactivity potent kunitz inhibitor of fibrinolysis
CN105163794B (zh) 2013-03-15 2020-03-27 塔里斯生物医药公司 具有药物可渗透部件的药物递送装置和方法
WO2015026813A1 (en) 2013-08-19 2015-02-26 Taris Biomedical Llc Multi-unit drug delivery devices and methods
CN104546668B (zh) * 2013-10-23 2019-03-05 国家卫生计生委科学技术研究所 液体硅橡胶为载体的药物缓控释***的制备及应用
PL2982352T3 (pl) * 2014-06-28 2019-01-31 Laboratorios Andrómaco S.A. Krążek szyjki macicy zawierający progesteron do długotrwałego, przedłużonego i ciągłego uwalniania, stosowany w celu zapobiegania przed przedwczesnym porodem
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US10894150B2 (en) 2015-04-23 2021-01-19 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
CN109071542B (zh) 2016-02-19 2021-07-20 凤凰分子设计公司 可用作rsk抑制剂的羧酰胺衍生物
JP6938545B2 (ja) 2016-05-20 2021-09-22 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
SG10201912376VA (en) 2016-12-09 2020-02-27 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
CR20200613A (es) 2018-06-13 2021-06-10 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
US20200030260A1 (en) 2018-07-27 2020-01-30 Xenon Pharmaceuticals Inc. Method for treating epilepsy
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
US11813354B1 (en) 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone
AU2020222056A1 (en) 2019-02-11 2021-10-07 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
AU2022349462A1 (en) 2021-09-24 2024-04-11 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
IL311056A (en) 2021-09-24 2024-04-01 Xenon Pharmaceuticals Inc Pyridine derivatives as sodium channel activators
WO2023049367A1 (en) 2021-09-24 2023-03-30 Xenon Pharmaceuticals Inc. Pyridinylacetamide derivatives as sodium channel activators
TW202404583A (zh) 2022-06-08 2024-02-01 加拿大商再諾製藥公司 吡啶胺衍生物及其作為鉀通道調節劑之用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
GB2079158B (en) * 1980-06-09 1985-01-09 Ahi Operations Ltd Intra-vaginal devices
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
IL116433A (en) * 1994-12-19 2002-02-10 Galen Chemicals Ltd INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS

Also Published As

Publication number Publication date
JP2001524124A (ja) 2001-11-27
NO995419L (no) 2000-01-07
EP0981327A2 (de) 2000-03-01
DK0981327T3 (da) 2003-03-10
IL132702A0 (en) 2001-03-19
DE69809222D1 (de) 2002-12-12
AU741482B2 (en) 2001-11-29
ES2187024T3 (es) 2003-05-16
EP0981327B1 (de) 2002-11-06
CA2288046C (en) 2006-10-03
NO995419D0 (no) 1999-11-05
US6416780B1 (en) 2002-07-09
CA2288046A1 (en) 1998-11-12
DE69809222T2 (de) 2003-08-14
WO1998050016A2 (en) 1998-11-12
WO1998050016A3 (en) 1999-02-04
CN1184957C (zh) 2005-01-19
PT981327E (pt) 2003-02-28
NZ501236A (en) 2002-02-01
CN1255056A (zh) 2000-05-31
AU7446998A (en) 1998-11-27

Similar Documents

Publication Publication Date Title
ATE227120T1 (de) Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen
WO2003077972A8 (en) Implantable drug delivery system
AU1227899A (en) Osmotic medicament releasing system
ID21259A (id) Sistim penyaluran obat untuk dua atau lebih bahan-bahan aktif
CA2298245A1 (en) Matrix controlled release device
GB2341550A (en) Gastroretentive controlled release microspheres for improved drug delivery
ES2192226T3 (es) Composicion farmaceutica oral que contiene agentes activos antimicrobianos y pantoprazol de liberacion prolongada.
EP1504758A3 (de) Formulierungen mit kontrollierter Abgabe überzogen mit wässrigen Dispersionen von Ethylcellulose.
PT1238660E (pt) Distribuicao sustentada de um agente activo utilizando um sistema implantavel
BR0014929A (pt) Dispositivo para distribuição de medicamento, e, processo para distribuir um agente farmaceuticamente ativo para um tecido alvo dentro de um corpo
FR2774288B1 (fr) Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
BG108516A (en) Pharmaceutical formulation
BR9902528A (pt) Sistema implantável e implante destinado à administração subcutânea ou local
SI1017392T1 (en) Medicament formulation with a controlled release of an active agent
AU1495595A (en) Sustained-release dosage forms of alfuzosin hydrochloride
HRP20010684B1 (en) Directly compressible matrix for controlled release of single daily doses of clarithromycin
WO1998026767A3 (en) Site-specific controlled release dosage formulation for mesalamine
HK1060691A1 (en) Ion-strength independent sustained release pharmaceutical formulation
MY129726A (en) Active ingredient combination (e.g. galanthamine or desoxypeganine with acamprosate or memantine) for treating a dependence on addictive substances or narcotics
EP1106609A3 (de) Aminoalkohol-Derivat und Medikament, das dieses Derivat enthält
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz
NZ309697A (en) Novel formulation for peptide release
NZ324674A (en) Rapid release tablet comprising tolfenamic acid, alginic acid and a superdisintegrant
ATE236621T1 (de) Niedrig dosierte tabletten, und verfahren zur herstellung
ZA9711660B (en) Therapeutic agent and treatment for canine intractable dermatitis.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0981327

Country of ref document: EP

REN Ceased due to non-payment of the annual fee